Timing of anticoagulation therapy in patients admitted with a primary diagnosis of ischemic stroke or transient ischemic attack due to non-valvular atrial fibrillation

Claudia Martin Diaz  
*Miami Cancer Institute*, ClaudiaMart@baptisthealth.net

Eduardo Guizan Corrales  
*Miami Cancer Institute*, eduardoag@baptisthealth.net

Felipe De Los Rios La Rosa  
*Miami Neuroscience Institute*, felipedl@baptisthealth.net

Heidi Clarke  
*Baptist Hospital of Miami*, heidic@baptisthealth.net

Jonatha Kline  
*Baptist Hospital of Miami*, JonathanDK@baptisthealth.net

Citation  
Martin Diaz, Claudia; Guizan Corrales, Eduardo; De Los Rios La Rosa, Felipe; Clarke, Heidi; Kline, Jonatha; Marrero, Sylvia; Gopalani, Radhan; and Belnap, Star, "Timing of anticoagulation therapy in patients admitted with a primary diagnosis of ischemic stroke or transient ischemic attack due to non-valvular atrial fibrillation" (2019). *All Publications*. 3482.  
https://scholarlycommons.baptisthealth.net/se-all-publications/3482

This Conference Poster – Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.
Authors
Claudia Martin Diaz, Eduardo Guizan Corrales, Felipe De Los Rios La Rosa, Heidi Clarke, Jonatha Kline, Sylvia Marrero, Radhan Gopalani, and Star Belnap
**BACKGROUND**

Approximately 13-26% of all acute ischemic strokes are related to atrial fibrillation (AF) and are associated with increased risk of systemic embolism and death. Anticoagulants (AC) are recommended after an ischemic stroke or transient ischemic attack (TIA) secondary to AF; however, the main challenge in current practice is determining the appropriate time of initiation. There is increased risk of both recurrent ischemic stroke and hemorrhagic transformation (HT) within the first two weeks following a primary stroke. According to the American Heart Association/American College of Cardiology (AHA/ACC) Atrial fibrillation guidelines, AC initiation is recommended between 4-14 days after event. Factors contributing to the risk of HT include use of thrombolytics or AC, baseline infarct size, presence of microhemorrhages, and mechanical thrombectomy procedure. This retrospective study will review patients with AF who subsequently developed an ischemic stroke or TIA. Time of AC initiation, use of thrombolytics, in-patient recurrent stroke or HT, and appropriateness of AC utilization will be reviewed.

**PURPOSE**

To assess the timing of AC initiation in patients presenting with ischemic stroke or TIA due to AF, and to determine potential areas for improvement to facilitate safe and effective use.

**METHODS**

- Single-center, retrospective chart review
  - Deemed as a performance improvement initiative per the BHSF IRB
  - Inclusion criteria:
    - Hospitalized adult patients ≥ 18 years of age
    - Acute ischemic stroke or TIA
    - Known or new-onset AF
    - Received AC
  - Exclusion criteria:
    - Contraindication to AC (e.g., ongoing bleeding, mechanical heart valve prosthesis, HT)
    - Unable to tolerate CT scan
    - Pregnancy
  - Primary outcome:
    - Time to AC initiation in patients post ischemic stroke or TIA due to AF
  - Secondary outcomes:
    - Type of AC started
    - Time to AC initiation if the patient received thrombolytic therapy at admission
    - In-patient recurrent stroke or HT
    - Appropriateness of AC on admission and discharge

**RESULTS**

### Patient Characteristics

<table>
<thead>
<tr>
<th>Demographics</th>
<th>N = 96</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years (range)</td>
<td>81 (54-89)</td>
</tr>
<tr>
<td>Gender—female, n (%)</td>
<td>50 (52)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>Hispanic, n (%)</td>
<td>50 (52)</td>
</tr>
<tr>
<td>Whites, n (%)</td>
<td>34 (35)</td>
</tr>
<tr>
<td>African American, n (%)</td>
<td>11 (11)</td>
</tr>
<tr>
<td>Median length of stay, days (range)</td>
<td>6 (1-89)</td>
</tr>
<tr>
<td>AC prescribed prior to admission, n (%)</td>
<td>39 (41)</td>
</tr>
<tr>
<td>Stroke classification—ischemic, n (%)</td>
<td>87 (91)</td>
</tr>
</tbody>
</table>

### Primary Outcomes

| Median time to AC initiation, days (range) | 3 (0.21-32) |

### Secondary Outcomes

**AC Initiated**

<table>
<thead>
<tr>
<th>N = 96</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apixaban, n (%)</td>
</tr>
<tr>
<td>Rivaroxaban, n (%)</td>
</tr>
<tr>
<td>Dabigatran, n (%)</td>
</tr>
<tr>
<td>Warfarin, n (%)</td>
</tr>
<tr>
<td>Enoxaparin, n (%)</td>
</tr>
<tr>
<td>Heparin, n (%)</td>
</tr>
<tr>
<td>AC initiation deferred to post-discharge, n (%)</td>
</tr>
</tbody>
</table>

**DISCUSSION**

- 61% of patients were started on AC during hospital course
- Median time to AC initiation in ischemic stroke/TIA was 3 days
- Initiation of AC therapy was planned and/or deferred to post-discharge in 39% of the patients
- Overall, 97% of the patients who were initiated AC therapy received it within 14 days (39% within 4-14 and 58% within 0-4 days)
- Average time to AC in patients who received thrombolytic therapy, underwent thrombectomy, or had a combination of both, was ~5 days
- In-patient symptomatic HT occurred in 3 patients, their average NIHSS score on admission was 11
- There was an 11% increase in the number of patients receiving appropriate AC upon discharge when compared to admission
- Factors contributing to delayed or deferred AC therapy included occurrence of HT, increased bleeding risk, or surgical procedures

**LIMITATIONS**

- Small sample size
- Initiation time of AC prescribed after discharge was not analyzed
- NIHSS score was not always available in the electronic health record
- NIHSS score was used as a surrogate measure for stroke severity

**CONCLUSION**

Patients were started on AC for secondary stroke prevention approximately four days following primary stroke/TIA. Early onset of AC was not associated with a significantly increased risk of hemorrhage.

**REFERENCES**